FDA DEVICE FACTS
LeukoStrat CDx FLT3 Mutation Assay
Invivoscribe Technologies, Inc.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
The LeukoStrat® CDx FLT3 Mutation Assay is a PCR-based, in vitro diagnostic test designed to detect internal tandem duplication (ITD) mutations and the tyrosine kinase domain (TKD) mutations D835 and I836, in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from PB or BM aspirates of patients diagnosed with acute myelogenous leukemia (AML).
The LeukoStrat® CDx FLT3 Mutation Assay is used as an aid in the selection of patients with AML for whom midostaurin (RYDAPT®) treatment is being considered.
The LeukoStrat® CDx FLT3 Mutation Assay is to be performed only at Laboratory for Personalized Molecular Medicine (LabPMM) LLC, a single laboratory site located at 6330 Nancy Ridge Dr., San Diego, CA 92121.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。